glp 1 parkinson's disease and neuroprotection Are GLP-1 diabetes drugs like Ozempic coming for disease? — Parkinson Secrets PDF] Novel dual GLP-1/GIP receptor

Cardiovascular endpoint studies have revolutionized the therapy of patients with diabetes, but they are lacking in the context of diabetes due to pituitary diseases

In addition, These incretin hormones bind to receptors in the pancreas to attenuate rising postprandial glucose levels

Liraglutide protects renal mesangial cells against hyperglycemiamediated mitochondrial apoptosis by activating the ERKYap signaling pathway and upregulating Sirt3 expression

Bioinformatics 22 , 623625 (2006)

Treatments based on GLP-1, which are now used to treat diabetes by increasing insulin production and protecting pancreatic cells, may provide an unanticipated advantage for diabetic patients who have PC, despite the fact that obesity and IR increase the risk of both cancer and T2D

The hesitation is understandable